Table 2.
Lipoprotein subclasses at baseline and 96 weeks in individuals with and without NASH resolution
| Resolution of NASH at 96 weeks | Adjusted* | |||
|---|---|---|---|---|
| Lipoprotein Subclass and Particle Size | Resolved (N=57) | Not resolved (N=60) | Geometric Mean Ratio (Resolved vs. Not resolved) | P |
| More Atherogenic | ||||
| Small and Medium LDL | ||||
| IVa (nmol/L) | ||||
| Geometric Mean (95% CI) | ||||
| Baseline | 59.2 (51.1, 68.5) | 69.7 (60.4, 80.3) | 0.80 | 0.01 |
| 96 weeks | 60.4 (52.3, 69.7) | 76.7 (66.4, 88.6) | 0.79 | 0.004 |
| Ratio of geometric means (GM96/GMBL) | 1.021 (0.892, 1.168) | 1.101 (0.979, 1.237) | 0.87 | 0.16 |
| IIIb (nmol/L) | ||||
| Geometric Mean (95% CI) | ||||
| Baseline | 59.7 (49.2, 72.5) | 75.3 (62.5, 90.7) | 0.74 | 0.007 |
| 96 weeks | 56.4 (46.9, 68.0) | 81.0 (68.1, 96.4) | 0.70 | 0.002 |
| Ratio of geometric means (GM96/GMBL) | 0.945 (0.814, 1.097) | 1.076 (0.940, 1.232) | 0.83 | 0.11 |
| IIIa (nmol/L) | ||||
| Geometric Mean (95% CI) | ||||
| Baseline | 157.1 (131.2, 188.1) | 201.2 (172.1, 235.2) | 0.73 | 0.003 |
| 96 weeks | 145.2 (122.5, 172.0) | 210.3 (181.1, 244.1) | 0.70 | 0.003 |
| Ratio of geometric means (GM96/GMBL) | 0.924 (0.803, 1.063) | 1.045 (0.933, 1.171) | 0.88 | 0.28 |
| VLDL Subclass | ||||
| Small (nmol/L) | ||||
| Geometric Mean (95% CI) | ||||
| Baseline | 54.6 (49.3, 60.3) | 56.7 (51.7, 62.3) | 0.98 | 0.72 |
| 96 weeks | 55.7 (50.0, 62.0) | 61.7 (56.5, 67.3) | 0.90 | 0.11 |
| Ratio of geometric means (GM96/GMBL) | 1.020 (0.923, 1.128) | 1.086 (1.006, 1.174) | 0.91 | 0.17 |
| Medium (nmol/L) | ||||
| Geometric Mean (95% CI) | ||||
| Baseline | 51.3 (44.4, 59.3) | 58.1 (51.4, 65.6) | 0.86 | 0.03 |
| 96 weeks | 52.1 (45.3, 60.0) | 64.7 (57.8, 72.5) | 0.81 | 0.01 |
| Ratio of geometric means (GM96/GMBL) | 1.015 (0.885, 1.165) | 1.115 (1.008, 1.232) | 0.88 | 0.16 |
| Large (nmol/L) | ||||
| Geometric Mean (95% CI) | ||||
| Baseline | 16.5 (13.6, 20.0) | 20.1 (17.1, 23.7) | 0.77 | 0.003 |
| 96 weeks | 16.3 (13.8, 19.3) | 21.8 (18.5, 25.6) | 0.75 | 0.004 |
| Ratio of geometric means (GM96/GMBL) | 0.989 (0.834, 1.173) | 1.081 (0.961, 1.216) | 0.88 | 0.23 |
| Less Atherogenic (Large Peak and Phenotype A) | ||||
| LDL Size Measurements | ||||
| LDL Peak mean (Å) | ||||
| Geometric Mean (95% CI) | ||||
| Baseline | 218.4 (216.7, 220.2) | 217.0 (215.4, 218.6) | 1.01 | 0.009 |
| 96 weeks | 220.0 (218.2, 221.8) | 216.2 (214.5, 217.8) | 1.02 | <0.001 |
| Ratio of geometric means (GM96/GMBL) | 1.007 (1.000, 1.014) | 0.996 (0.992, 1.001) | 1.01 | 0.004 |
| LDL Phenotype | OR | |||
| Baseline | 30 (53%) | 26 (43%) | 1.00 | |
| A (Favorable) | 9 (16%) | 6 (10%) | 0.67 | 0.04 |
| I (Intermediate) | 18 (32%) | 28 (47%) | 0.22 | |
| B (Atherogenic) | ||||
| 96 weeks | ||||
| A (Favorable) | 33 (58%) | 20 (33%) | 1.00 | |
| I (Intermediate) | 8 (14%) | 10 (17%) | 0.33 | 0.003 |
| B (Atherogenic) | 16 (28%) | 30 (50%) | 0.12 | |
*
Adjusted for treatment group, age at biopsy (years), gender, ethnicity, baseline BMI, HOMA-IR, baseline triglyceride level (mg/dL), use of statin or non-statin lipid lowering medication at baseline and/or during follow-up, and for ratio measures, the baseline value of the lipoprotein subfraction. Benjamini-Hochberg false discovery rate adjusted threshold for statistical significance at baseline: P<0.044; 96-weeks: P<0.044, and GM96/GMBL ratios: P<0.007.